{"filings":[{"id":444876,"accession_number":"0001437749-26-017116","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2026-05-14T21:11:29+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuo Therapeutics Q1 revenues up 169% YoY to $1.3M; operating loss narrows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $1.3M, including $1.22M product sales, up 169% YoY and 20% sequential.","Aurix branded product revenue rose over 30% sequentially versus Q4 2025.","Net operating loss improved to $446,000 from $745,000 in Q1 2025.","Entered $1.0M Loan and Security Agreement to fund growth as company approaches breakeven.","CEO cites strong Aurix demand and favorable Medicare reimbursement shift for autologous PRP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1302115.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101194,"accession_number":"0001437749-26-002078","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Nuo Therapeutics secures up to $1.6M loan with 10%-12% PIK interest paid in warrants; insider participation","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan agreement for $1.0M initial + $600K second tranche (Sept 30, 2026); $1.0M funded Jan 23, 2026.","Interest 10% annual on initial note, rising to 12% if second tranche is taken; accrued interest paid only in warrants at maturity.","Principal repaid in 8 equal quarterly installments from Mar 31, 2027 to Dec 31, 2028; early prepayment fee 1.5-2.75% of principal paid in warrants.","Lenders include director/10% owner Scott Pittman ($200K) and >5% owner Paul Jacobs ($300K); each received initial and potential second warrants.","Warrants exercisable at $1.50/share, expiring Jan 23, 2031; up to 226,000 interest warrant shares issuable at maximum borrowing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117540,"accession_number":"0001437749-25-038091","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nuo Therapeutics shareholders elect four directors and ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All four director nominees elected: David E. Jorden, Paul D. Mintz, Scott M. Pittman, C. Eric Winzer.","Ratification of MaloneBailey LLP as auditor approved with 35,917,807 for, 12,899 against.","Advisory vote on named executive officer compensation passed with 33,653,458 for, 40,106 against.","Broker non-votes of 2,237,142 noted for director election and say-on-pay items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117539,"accession_number":"0001437749-25-030813","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["5.02","5.08","8.01"],"status":"ready","headline":"Nuo Therapeutics raises CEO and COO salaries, sets Dec 16 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO David E. Jorden salary increased to $325,000 effective Oct 1, 2025.","COO Peter A. Clausen salary increased to $290,000 effective same date.","Annual meeting scheduled for Dec 16, 2025 at Houston principal executive office.","Shareholder proposals and director nominations deadline is Oct 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150713,"accession_number":"0001437749-25-017214","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Nuo Therapeutics enters interim sales agency agreement with Smith+Nephew for Aurix products","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Distribution Agreement grants Smith+Nephew interim sales agent role for Nuo Aurix brand to certain Smith+Nephew customers.","Smith+Nephew receives commission on net sales of Nuo branded products sold to its customers under interim arrangement.","Interim agency terminates by Dec 31, 2025 or earlier with 30 days written notice.","Underlying five-year Distribution Agreement for Nuo to supply private-label Aurix to Smith+Nephew remains in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203270,"accession_number":"0001437749-24-029602","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nuo Therapeutics raises $849k in private placement of 1.13M shares at $0.75/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $849,125 from sale of 1,132,167 shares at $0.75 per share.","Principal stockholder Charles E. Sheedy invested $93,750 in the placement.","Proceeds to be used for working capital; shares outstanding increase to 46,598,405.","Shares sold under Section 4(a)(2) and Rule 506 without registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219613,"accession_number":"0001437749-24-021407","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pacific Medical exercises full warrant for 356,889 shares of Nuo Therapeutics common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pacific Medical exercised warrant for 270,000 shares at $0.56/share, raising $151,200 in cash proceeds.","Remaining 230,000 shares exercised on cashless basis, resulting in issuance of 86,889 shares.","Total shares issued: 356,889; outstanding shares now 45,466,238."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219612,"accession_number":"0001437749-24-019961","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Nuo Therapeutics dismisses auditor Marcum, engages MaloneBailey; cites material weaknesses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective June 7, 2024, dismissed Marcum LLP as independent auditor; engaged MaloneBailey, LLP for FY 2024.","Marcum's reports for FY2023 and FY2022 included going-concern explanatory paragraphs.","Identified material weaknesses: insufficient accounting staff and lack of effective internal control over financial reporting.","No disagreements with Marcum on accounting principles or audit scope prior to dismissal.","Marcum's letter to SEC agreeing with disclosures filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219611,"accession_number":"0001437749-24-017754","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nuo Therapeutics raises $650,875 in private placement of 867,833 shares at $0.75/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $650,875 from sale of 867,833 shares of common stock at $0.75 per share.","Insiders invested $187,500 total: Scott Pittman ($101,250), Peter Clausen ($11,250), Charles Sheedy ($75,000).","Proceeds to be used for working capital; shares sold under Rule 506(b) of the Securities Act.","Post-closing shares outstanding increased to 45,109,349."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}